Press Releases
Cavion to Present Results of Phase 2 Essential Tremor Clinical Trial in Platform Presentation at the American Academy of Neurology | April 24, 2019
Presentation to provide overview of Phase 2 T-CALM study design, results and clinical path forward
Presentation to provide overview of Phase 2 T-CALM study design, results and clinical path forward
Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model | November 05, 2018
Data to be Presented in Poster at the Society for Neuroscience Annual Meeting
Data to be Presented in Poster at the Society for Neuroscience Annual Meeting
Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study | October 05, 2018
~Totality of Data Demonstrates CX-8998 is Well Tolerated with Compelling Evidence of Efficacy Despite Missing Primary Endpoint Measured Using Central Video Rating~
~Totality of Data Demonstrates CX-8998 is Well Tolerated with Compelling Evidence of Efficacy Despite Missing Primary Endpoint Measured Using Central Video Rating~
Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial | October 04, 2018
Cavion’s Results to be Featured as Late Breaker at International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong
Cavion’s Results to be Featured as Late Breaker at International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong
Cavion Appoints Julia P. Gregory Executive Chair | September 11, 2018
Julia Gregory Brings to Cavion a Wealth of Experience and Deep Expertise in the Biopharma Industry
Julia Gregory Brings to Cavion a Wealth of Experience and Deep Expertise in the Biopharma Industry
-
Cavion Raises $26.1 MM Series A Financing | January 06, 2017
Financing will support development of novel treatments for neurological diseases -
Cavion to Present Clinical Trial Preliminary Results at ASTRO | September 26, 2016
Yale studies the combination of Cavion’s T-type calcium channel blocker mibefradil with hypofractionated radiation -
Cavion Names Senior Scientific and Business Advisors | February 01, 2016
Llinas and Lynch Bring Decades of Neuroscience and Strategic Insight to Company -
Cavion to Deliver Three Presentations at SNO, the World's Leading Multidisciplinary Brain Cancer Conference | November 19, 2015
Data Suggests Cavion's T-type Calcium Channel Blocker Mibefradil is Effective Against Glioblastoma -
Cavion LLC Closes $5M Round of Convertible Debt | November 10, 2015
Financing Will Support Platform Development
In the News
-
BioCentury
Cavion Planning Phase III for Essential tremor Candidate Despite Phase II Miss -
ENDPOINTS NEWS
Eli Lilly, Novartis back a $26M round for Cavion’s work on neurological diseases -
BioCentury
Cavion raises $26.1M series A -
Fighting Gliomas by Inhibiting DNA Repair
Yale Cancer Center Breakthroughs Year in Review 2014
Contact Us
Cavion
Charlottesville Office
600 East Water Street, Suite E
Charlottesville, VA 22902
(Please contact the Charlottesville Office for all accounting related communications)
Cambridge Office
1 Broadway, 14 FL
Cambridge, MA 02142
434.200.8442
info@cavionpharma.com
Directions